Addex's 2010 loss rises as lead product nears Phase IIb
23 February 2010
Simon Varcoe
Please Login to read the full article.
23 February 2010
Simon Varcoe
simon.varcoe@informa.com
Addex Pharmaceuticals' net loss was lower than analysts' expectations last year as it controlled its R&D and general and administration expenses.
However, the Swiss company's net loss still nearly doubled to CHF42.7 million ($39.7 million) as it moved its lead unpartnered product, ADX48621...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
FEATURES
- DKSH highlights one-stop benefits as it builds Asia market expansion services
- Merck BioVentures: where biosimilars make a difference
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
